These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 17568997)

  • 1. No association of MDM2 SNP309 with risk of glioblastoma and prognosis.
    El Hallani S; Marie Y; Idbaih A; Rodero M; Boisselier B; Laigle-Donadey F; Ducray F; Delattre JY; Sanson M
    J Neurooncol; 2007 Dec; 85(3):241-4. PubMed ID: 17568997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of a single nucleotide polymorphism of MDM2 in glioblastoma multiforme.
    Khatri RG; Navaratne K; Weil RJ
    J Neurosurg; 2008 Nov; 109(5):842-8. PubMed ID: 18976073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of breast cancer outcome with status of p53 and MDM2 SNP309.
    Boersma BJ; Howe TM; Goodman JE; Yfantis HG; Lee DH; Chanock SJ; Ambs S
    J Natl Cancer Inst; 2006 Jul; 98(13):911-9. PubMed ID: 16818855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Common polymorphisms in the MDM2 and TP53 genes and the relationship between TP53 mutations and patient outcomes in glioblastomas.
    Zawlik I; Kita D; Vaccarella S; Mittelbronn M; Franceschi S; Ohgaki H
    Brain Pathol; 2009 Apr; 19(2):188-94. PubMed ID: 18462472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic impact of molecular markers in a series of 220 primary glioblastomas.
    Houillier C; Lejeune J; Benouaich-Amiel A; Laigle-Donadey F; Criniere E; Mokhtari K; Thillet J; Delattre JY; Hoang-Xuan K; Sanson M
    Cancer; 2006 May; 106(10):2218-23. PubMed ID: 16568472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis.
    Ohmiya N; Taguchi A; Mabuchi N; Itoh A; Hirooka Y; Niwa Y; Goto H
    J Clin Oncol; 2006 Sep; 24(27):4434-40. PubMed ID: 16983111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
    Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
    Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors.
    Idbaih A; Boisselier B; Marie Y; Sanson M; El Hallani S; Crinière E; Fourtassi M; Paris S; Carpentier C; Rousseau A; Mokhtari K; Combadière C; Laigle-Donadey F; Hoang-Xuan K; Delattre JY
    Brain Res; 2008 Mar; 1198():16-20. PubMed ID: 18262501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between MDM2 and p53 alterations in colorectal cancer and their involvement and prognostic value in the Tunisian population.
    Chaar I; Amara S; Khiari M; Ounissi D; Dhraif M; Ben Hamida AE; Gharbi L; Mzabi S; Bouraoui S
    Appl Immunohistochem Mol Morphol; 2013 May; 21(3):228-36. PubMed ID: 22914606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL.
    Dong HJ; Fang C; Fan L; Zhu DX; Wang DM; Zhu HY; Zhuang Y; Miao KR; Liu P; Xu W; Li JY
    Int J Cancer; 2012 May; 130(9):2054-61. PubMed ID: 21647873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR, p53, IDH-1 and MDM2 immunohistochemical analysis in glioblastoma: therapeutic and prognostic correlation.
    Montgomery RM; Queiroz Lde S; Rogerio F
    Arq Neuropsiquiatr; 2015 Jul; 73(7):561-8. PubMed ID: 26200049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes.
    Newcomb EW; Cohen H; Lee SR; Bhalla SK; Bloom J; Hayes RL; Miller DC
    Brain Pathol; 1998 Oct; 8(4):655-67. PubMed ID: 9804374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer.
    Campbell IG; Eccles DM; Choong DY
    Cancer Lett; 2006 Aug; 240(2):195-7. PubMed ID: 16239061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired outcome.
    Falk IJ; Willander K; Chaireti R; Lund J; Nahi H; Hermanson M; Gréen H; Lotfi K; Söderkvist P
    Eur J Haematol; 2015 Apr; 94(4):355-62. PubMed ID: 25156865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mdm2 SNP309 G-variant is associated with invasive growth of human urinary bladder cancer.
    Hitzenbichler F; Stoehr CG; Rogenhofer M; Wieland WF; Ruemmele P; Hartmann A; Stoehr R
    Pathobiology; 2014; 81(2):53-9. PubMed ID: 24217660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MDM2 SNP309 modifies the prognostic significance of the p53 mutational status in patients with ovarian cancer.
    Hofstetter G; Berger A; Bauer EM; Schuster E; Wolf A; Chamson M; Müller-Holzner E; Reimer D; Braicu EI; Sehouli J; Ulmer H; Cacsire Castillo-Tong D; Zeillinger R; Concin N
    Oncol Rep; 2012 Mar; 27(3):673-7. PubMed ID: 22134502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MDM2 SNP309 promoter polymorphism confers risk for hereditary melanoma.
    Thunell LK; Bivik C; Wäster P; Fredrikson M; Stjernström A; Synnerstad I; Rosdahl I; Enerbäck C
    Melanoma Res; 2014 Jun; 24(3):190-7. PubMed ID: 24625390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia.
    Gryshchenko I; Hofbauer S; Stoecher M; Daniel PT; Steurer M; Gaiger A; Eigenberger K; Greil R; Tinhofer I
    J Clin Oncol; 2008 May; 26(14):2252-7. PubMed ID: 18467716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A functional SNP in the MDM2 promoter, pigmentary phenotypes, and risk of skin cancer.
    Nan H; Qureshi AA; Hunter DJ; Han J
    Cancer Causes Control; 2009 Mar; 20(2):171-9. PubMed ID: 18814047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MDM2 SNP309 is associated with high grade node positive breast tumours and is in linkage disequilibrium with a novel MDM2 intron 1 polymorphism.
    Paulin FE; O'Neill M; McGregor G; Cassidy A; Ashfield A; Ali CW; Munro AJ; Baker L; Purdie CA; Lane DP; Thompson AM
    BMC Cancer; 2008 Oct; 8():281. PubMed ID: 18828900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.